Accepted at 1:37 a.m. Nov, 01, 2023 by Aaron
Author: Aaron
Related Note: 1514576041266
Rationale for change

I know this is a bit controversial but AMBOSS and UTD both confirm that when a pt is NOT on ART and has a count <50, they should be on a macrolide.
https://next.amboss.com/us/shared/questions/rZg9f1F5d/21
https://www.uptodate.com/contents/overview-of-prevention-of-opportunistic-infections-in-patients-with-hiv?search=hiv%20prophylaxis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H96943128

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Picmonic
Empty field
Pixorize
Empty field
Physeo
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step2_v12::#B&B::08_Infectious_Disease::03_HIV::01_HIV_Infection::Extra #PANCE::INFECTIOUS_DISEASE::mycobacterial_diseases #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::26_Antituberculous_drugs::*Rifamycins #AK_Step2_v12::Original_decks::Dorian::im::ome::infection::hiv #AK_Step2_v12::#UWorld::Step::3252 #AK_Step2_v12::#Resources_by_rotation::IM::ome::infection::hiv #AK_Step2_v12::#SketchyIM::09_Infectious_Diseases::Retired_Lessons::04_HIV_&_AIDS::02_AIDS_SOAP_[OLD_VERSION] #AK_Step1_v12::^Other::^EXPN #AK_Step2_v12::Original_decks::MedicalArk::im::amboss #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::02_Inhibitors_of_Bacterial_Protein_Synthesis::02_Macrolides #AK_Step1_v12::#B&B::14_Infectious_Disease::02_Bacteria::08_Mycobacteria #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::24_Pyrazinamide_Ethambutol_Dapsone_and_Clofazimine #AK_Other::!AK_UpdateTags::Table::HIV_Opportunistic_Prophylaxis #AK_Step2_v12::#B&B::08_Infectious_Disease::03_HIV::03_HIV_Complications::Extra #AK_Step1_v12::^Other::^FA_Updates::FA2018 #AK_Other::!AK_UpdateTags::AnKing_Image::Mujeeb::HIV_infection_management #AK_Step2_v12::#Resources_by_rotation::IM::amboss_medicalark #AK_Step1_v12::#FirstAid::03_Microbiology::07_Antimicrobials::27_Antimycobacterial_therapy #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#SketchyPharm::07_Antimicrobials::03_Antimycobacterials::02_Leprosy_Drugs::zanki_extra #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::16_Macrolides #AK_Step1_v12::#Physeo::09_Pharm::05_Antibiotics::22_Dapsone,_Rifamycins,_Clofazimine_(Leprosy_Drugs) #AK_Step2_v12::#UWorld::COMLEX::100060 #AK_Step2_v12::#Subjects::Microbiology::01_Bacteria::08_Mycobacteria::Mycobacterium_Avium_Complex #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::23_Rifamycins #AK_Step1_v12::#OME::PreClinical::Microbiology::Microbiology_2::Antibacterials::Antimycobacterials #AK_Step2_v12::#Subjects::Microbiology::01_Bacteria::08_Mycobacteria::Mycobacterium_Avium_Complex::Prophylaxis #AK_Step2_v12::#FirstAid::14_Pulm::07_Mycobacterial_Infections::02_Nontuberculous_Mycobacteria #AK_Step2_v12::#AMBOSS::IF0Yj3 #AK_Step1_v12::#SketchyMicro::01_Bacteria::08_Mycobacteria::03_Mycobacterium_avium_intracellulare,_Mycobacterium_scrofulaceum,_Mycobacterium_marinum #AK_Step1_v12::#Bootcamp::Microbiology::36_Antibiotics::14_Macrolides #AK_Step1_v12::#Bootcamp::Microbiology::35_Opportunistic_Infections::07_Cytomegalovirus,_Disseminated_Mycobacterial_Non-Tuberculous_Disease #AK_Other::!AK_UpdateTags::AnKing_Image::!Subjects::Microbiology::HIV_infection_management #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield